UNJ Stock Overview
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
The United Laboratories International Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.00 |
| 52 Week High | HK$1.17 |
| 52 Week Low | HK$0.66 |
| Beta | 0.045 |
| 1 Month Change | -10.71% |
| 3 Month Change | 29.87% |
| 1 Year Change | 41.84% |
| 3 Year Change | 49.25% |
| 5 Year Change | 99.20% |
| Change since IPO | 194.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| UNJ | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -14.5% | -3.1% | -2.0% |
| 1Y | 41.8% | -31.9% | -0.3% |
Return vs Industry: UNJ exceeded the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: UNJ exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| UNJ volatility | |
|---|---|
| UNJ Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UNJ has not had significant price volatility in the past 3 months.
Volatility Over Time: UNJ's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 15,000 | n/a | www.tul.com.cn |
The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin products, nervous system drugs, vitamins, veterinary drugs, and vacant gelatin capsules, as well as active pharmaceutical ingredients and intermediate products.
The United Laboratories International Holdings Limited Fundamentals Summary
| UNJ fundamental statistics | |
|---|---|
| Market cap | €2.03b |
| Earnings (TTM) | €350.11m |
| Revenue (TTM) | €1.78b |
5.8x
P/E Ratio1.1x
P/S RatioIs UNJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNJ income statement (TTM) | |
|---|---|
| Revenue | CN¥13.74b |
| Cost of Revenue | CN¥7.41b |
| Gross Profit | CN¥6.33b |
| Other Expenses | CN¥3.63b |
| Earnings | CN¥2.70b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.49 |
| Gross Margin | 46.11% |
| Net Profit Margin | 19.66% |
| Debt/Equity Ratio | 11.7% |
How did UNJ perform over the long term?
See historical performance and comparison